

DAFTAR PUSTAKA

1. Ahmed, S. Advances in the management of colorectal cancer: From biology to treatment. *International Journal of Colorectal Disease*. 2014;29(9), pp. 1031–1042. doi: 10.1007/s00384-014-1928-5.
2. Ajouz, H., Mukherji, D. and Shamseddine, A. Secondary bile acids: An underrecognized cause of colon cancer. *World Journal of Surgical Oncology*, 2014;12(1), pp. 1–5. doi: 10.1186/1477-7819-12-164.
3. Alzahrani, S. M., Al Doghaither, H. A. and Al-Ghafar, A. B. General insight into cancer: An overview of colorectal cancer (review). *Molecular and Clinical Oncology*. 2021;15(6). doi: 10.3892/MCO.2021.2433.
4. Amersi, F., Agustin, M. and Ko, C. Y. Colorectal cancer: Epidemiology and health services research. *Surgical Oncology Clinics of North America*. 2006;15(1), pp. 21–37. doi: 10.1016/j.soc.2005.08.003.
5. Aran, V. *et al.* Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality. *Clinical Colorectal Cancer*. 2016;15(3), pp. 195–203. doi: 10.1016/j.clcc.2016.02.008.
6. Ardito F, Razionale F, Salvatore L, et al. Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection. *Cancers*. 2021 April. <https://www.mdpi.com/journal/cancers>.
7. Arnold, M. *et al.* Global patterns and trends in colorectal cancer incidence and mortality. *Gut*. 2017;66(4), pp. 683–691. doi: 10.1136/gutjnl-2015-310912.
8. Aykan, N. F. Red meat and colorectal cancer. *Oncology Reviews*. 2015;9(1), pp. 38–44. doi: 10.4081/oncol.2015.288.
9. Bachet, J. B. *et al.* BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases. *British Journal of Surgery*. 2019;106(9), pp. 1237–1247. doi: 10.1002/bjs.11180.
10. Barták, B. K. *et al.* Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. *Epigenetics*. 2017;12(9), pp. 751–763. doi: 10.1080/15592294.2017.1356957.

11. Bertero, L. *et al.* Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria—What has changed and why?. *Virchows Archiv.* 2018;472(4), pp. 519–531. doi: 10.1007/s00428-017-2276-y.
12. Brar, B. *et al.* Nanotechnology in Colorectal Cancer for Precision Diagnosis and Therapy. *Frontiers in Nanotechnology.* 2021;3(September), pp. 1–21. doi: 10.3389/fnano.2021.699266.
13. Bray, F. *et al.* Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. *International Journal of Cancer.* 2015;137(9), pp. 2060–2071. doi: 10.1002/ijc.29670.
14. Bronchud, M. *et al.* Molecular Basis of Cancer. *The Lancet.* 2000;356(Oct 14), p. 2000. doi: 10.1016/s0140-6736(05)74283-5.
15. Brown, K. G. M. *et al.* Management of colorectal cancer. *The BMJ.* 2019;366(August), pp. 1–7. doi: 10.1136/bmj.l4561.
16. Brudvik, K. W. *et al.* Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. *British Journal of Surgery.* 2015;102(10), pp. 1175–1183. doi: 10.1002/bjs.9870.
17. Brzacki, V. *et al.* Diabetes Mellitus: a Clinical Condition Associated with Metabolic Syndrome and Colorectal Cancer Risk. *Current Pharmacology Reports.* 2019;5(4), pp. 205–209. doi: 10.1007/s40495-019-00183-8.
18. Buchler, T. Microsatellite Instability and Metastatic Colorectal Cancer – A Clinical Perspective. *Frontiers in Oncology.* 2022;12(April), pp. 6–11. doi: 10.3389/fonc.2022.888181.
19. Carethers, J. M. and Doubeni, C. A. Causes of Socioeconomic Disparities in Colorectal Cancer and Intervention Framework and Strategies. *Gastroenterology.* 2020;158(2), pp. 354–367. doi: 10.1053/j.gastro.2019.10.029.
20. Carr, P. R. *et al.* Lifestyle factors and risk of sporadic colorectal cancer by microsatellite instability status: A systematic review and meta-analyses. *Annals of Oncology.* 2018;29(4), pp. 825–834. doi: 10.1093/annonc/mdy059.
21. Cascella, M. *et al.* Dissecting the mechanisms and molecules underlying the potential carcinogenicity of red and processed meat in colorectal cancer (CRC):

- An overview on the current state of knowledge. *Infectious Agents and Cancer*. 2018;13(1), pp. 1–8. doi: 10.1186/s13027-018-0174-9.
22. Casciato, D. and Territo, M. *Manual of Clinical Oncology*. 7th. ed. Philadelphia: Lippincott Williams & Wilkins; 2012
 23. Centelles, J. J. *General Aspects of Colorectal Cancer*. *ISRN Oncology*. 2012; pp. 1–19. doi: 10.5402/2012/139268.
 24. Chan, D. S. M. *et al.* Red and processed meat and colorectal cancer incidence: Meta-analysis of prospective studies. *PLOS ONE*. 2011;6(6). doi: 10.1371/journal.pone.0020456.
 25. Cheng, Y., Ling, Z. and Li, L. The Intestinal Microbiota and Colorectal Cancer. *Frontiers in Immunology*. 2020;11(November), pp. 1–13. doi: 10.3389/fimmu.2020.615056.
 26. Ciepela I, Szczepaniak M, Ciepela P, et al. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients. *Nature*. 2024. 14:4619
 27. Cisterna, B. A. *et al.* Targeted nanoparticles for colorectal cancer. *Nanomedicine*. 2016;11(18), pp. 2443–2456. doi: 10.2217/nmm-2016-0194.
 28. Dekker, E. *et al.* Colorectal cancer. *The Lancet*. 2019;394(10207), pp. 1467–1480. doi: 10.1016/S0140-6736(19)32319-0.
 29. Diener, M. K. and Fichtner-Feigl, S. Biomarkers in colorectal liver metastases: Rising complexity and unknown clinical significance?. *Annals of Gastroenterological Surgery*. 2021;5(4), pp. 477–483. doi: 10.1002/ags3.12454.
 30. Dunne, D. F. *et al.* Surgical management of colorectal liver metastases: a European perspective. *Hepatic Oncology*. 2014;1(1), pp. 121–133. doi: 10.2217/hep.13.3.
 31. De Falco, V. *et al.* How we treat metastatic colorectal cancer. *ESMO open*. 2020;4, p. e000813. doi: 10.1136/esmoopen-2020-000813.
 32. Engstrand J, Nilsson H, Strömberg C, et al. Colorectal cancer liver metastases – a population-based study on incidence, management and survival. *BMC Cancer*. 2018. 18:78
 33. Farhat, W. *et al.* Factors predicting recurrence after curative resection for rectal cancer: A 16-year study. *World Journal of Surgical Oncology*. 2019;17(1), pp.

- 1–10. doi: 10.1186/s12957-019-1718-1.
34. Ferlay, J. *et al.* Cancer statistics for the year 2020: An overview. *International Journal of Cancer*. 2021;149(4), pp. 778–789. doi: 10.1002/ijc.33588.
35. Fleming, M. *et al.* Colorectal carcinoma: Pathologic aspects. *Journal of Gastrointestinal Oncology*. 2012;3(3), pp. 153–173. doi: 10.3978/j.issn.2078-6891.2012.030.
36. Ford, A. C. *et al.* Diagnostic utility of alarm features for colorectal cancer: Systematic review and meta-analysis. *Gut*. 2008;57(11), pp. 1545–1552. doi: 10.1136/gut.2008.159723.
37. Gagnière, J. *et al.* Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. *Annals of Surgery*. 2020;271(1), pp. 147–154. doi: 10.1097/SLA.0000000000002968.
38. Gandomani, H. S. *et al.* Colorectal cancer in the world: incidence, mortality and risk factors. *Biomedical Research and Therapy*. 2017;4(10), p. 1656. doi: 10.15419/bmrat.v4i10.372.
39. Ganesh, K. *et al.* Immunotherapy in colorectal cancer: rationale, challenges and potentials. *Nat Rev Gastroenterol Hepatol*. 2019;16(6), pp. 113–166. doi: 10.1017/9781108333511.004.
40. Gao J, Zhuang L, He C, et al. Risk and prognostic factors in patients with colon cancer with liver metastasis. *Journal of International Medical Research*. 2023; Vol. 51(9) 1–16
41. Ghosh, N. *et al.* The Wnt signaling pathway: a potential therapeutic target against cancer. *Annals of the New York Academy of Sciences*. 2019;1443(1), pp. 54–74. doi: 10.1111/nyas.14027.
42. Goldstein, J. *et al.* Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). *Annals of Oncology*. 2014;25(5), pp. 1032–1038. doi: 10.1093/annonc/mdu100.
43. Guo, Y. *et al.* ERK/MAPK signalling pathway and tumorigenesis (Review). *Experimental and Therapeutic Medicine*. 2020, pp. 1997–2007. doi: 10.3892/etm.2020.8454.
44. Gupta, S. *et al.* Recommendations for Follow-Up after Colonoscopy and Polypectomy: A Consensus Update by the US Multi-Society Task Force on

- Colorectal Cancer. *American Journal of Gastroenterology*. 2020;115(3), pp. 415–434. doi: 10.14309/ajg.0000000000000544.
45. Guraya, S. Chemopreventive role of vitamin D in colorectal carcinoma. *Journal of Microscopy and Ultrastructure*. 2014;2(1), p. 1. doi: 10.1016/j.jmau.2013.09.001.
46. Hammond, W. A., Swaika, A. and Mody, K. Pharmacologic resistance in colorectal cancer: A review. *Therapeutic Advances in Medical Oncology*. 2016;8(1), pp. 57–84. doi: 10.1177/1758834015614530.
47. Han SA, et al. The clinical significance of microsatellite instability in patients with right-sided colorectal cancer. *Korean J Gastroenterol*. 2019;73(3):159-66.
48. Hao, M. *et al*. Which patients are prone to suffer liver metastasis? A review of risk factors of metachronous liver metastasis of colorectal cancer. *European Journal of Medical Research*. 2022;27(1), pp. 1–15. doi: 10.1186/s40001-022-00759-z.
49. Hashimoto, Y., Zumwalt, T. J. and Goel, A. DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer. *Epigenomics*. 2016;8(5), pp. 685–703. doi: 10.2217/epi-2015-0013.
50. Hermida, M. A., Dinesh Kumar, J. and Leslie, N. R. GSK3 and its interactions with the PI3K/AKT/mTOR signalling network. *Advances in Biological Regulation*. 2017;65, pp. 5–15. doi: 10.1016/j.jbior.2017.06.003.
51. Hnatyszyn, A. *et al*. Colorectal carcinoma in the course of inflammatory bowel diseases. *Hereditary Cancer in Clinical Practice*. 2019;17(1), pp. 1–9. doi: 10.1186/s13053-019-0118-4.
52. Hossain, M. S. *et al*. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies. *Cancer*. 2022;14(1732), pp. 1–25.
53. Huang W, et al. High concordance rate of capillary electrophoresis workflow for microsatellite instability analysis and mismatch repair (MMR) immunostaining in colorectal carcinoma. *PLOS ONE*. 2023 April. <https://doi.org/10.1371/journal.pone.0284227>.
54. Issa, I. A. and Nouredine, M. Colorectal cancer screening: An updated review of the available options. *World Journal of Gastroenterology*. 2017;23(28), pp.

- 5086–5096. doi: 10.3748/wjg.v23.i28.5086.
55. Ituarte HG, Nelson R, O’Leary MP, et al. Age-adjusted incidence rates of synchronous liver metastases for stage IV colorectal cancer compared by sex, race, and age group. *HPB*. 2022, 24, 1074–1081
 56. Jeo, W. and Subrata, F. The Survival Rate of Colorectal Cancer in dr. Cipto Mangunkusumo Hospital. *The New Ropanasuri : Journal of Surgery*. 2020;5(2), pp. 13–17. doi: 10.7454/nrjs.v5i2.1081.
 57. Johdi, N. A. and Sukor, N. F. Colorectal Cancer Immunotherapy: Options and Strategies. *Frontiers in Immunology*. 2020;11(September), pp. 1–18. doi: 10.3389/fimmu.2020.01624.
 58. Jones, R. P. *et al.* Precision surgery for colorectal liver metastases: Opportunities and challenges of omics-based decision making. *European Journal of Surgical Oncology*. 2017;43(5), pp. 875–883. doi: 10.1016/j.ejso.2017.02.014.
 59. Kanas, G. P. *et al.* Survival after liver resection in metastatic colorectal cancer: Review and meta-analysis of prognostic factors. *Clinical Epidemiology*. 2012;4(1), pp. 283–301. doi: 10.2147/CLEP.S34285.
 60. Keum, N. N. and Giovannucci, E. Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies. *Nature Reviews Gastroenterology and Hepatology*. 2019;16(12), pp. 713–732. doi: 10.1038/s41575-019-0189-8.
 61. Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. *Am J Pathol*. 1994. 145:148–156
 62. Kitsel, Y. *et al.* Colorectal Cancer Liver Metastases: Genomics and Biomarkers with Focus on Local Therapies. *Cancers*. 2023;15(6), p. 1679. doi: 10.3390/cancers15061679.
 63. Knijn, N. *et al.* KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. *British Journal of Cancer*. 2011;104(6), pp. 1020–1026. doi: 10.1038/bjc.2011.26.
 64. Kolligs, F. T. Diagnostics and epidemiology of colorectal cancer. *Visceral Medicine*. 2016;32(3), pp. 158–164. doi: 10.1159/000446488.
 65. Kranenburg, O., Speeten, K. van der and Hingh, I. de. Peritoneal Metastases

- From Colorectal Cancer: Defining and Addressing the Challenges. *Frontiers in Oncology*. 2021;11(March), pp. 1–11. doi: 10.3389/fonc.2021.650098.
66. Krasteva, N. and Georgieva, M. Promising Therapeutic Strategies for Colorectal Cancer Treatment Based on Nanomaterials. *Pharmaceutics*. 2022;14(6), pp. 1–38. doi: 10.3390/pharmaceutics14061213.
67. Kristina, S. A., Ayu Linda Permitasari, N. P. and Ahsan, A. The Premature Mortality Cost of Cancers Attributable to Secondhand Smoking in Indonesia. *Asian Pacific Journal of Cancer Care*. 2019;4(4), pp. 107–112. doi: 10.31557/apjcc.2019.4.4.107-112.
68. Lan, Y. T. *et al.* Improved outcomes of colorectal cancer patients with liver metastases in the era of the multidisciplinary teams. *International Journal of Colorectal Disease*. 2016;31(2), pp. 403–411. doi: 10.1007/s00384-015-2459-4.
69. Lawler, M. *et al.* Colorectal Cancer. *Abeloff's Clinical Oncology*. 6th ed. Elsevier Inc. 2019. doi: 10.1016/B978-0-323-47674-4.00074-8.
70. Lech, G. *et al.* Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. *World Journal of Gastroenterology*. 2016;22(5), pp. 1745–1755. doi: 10.3748/wjg.v22.i5.1745.
71. Lee MS, Menter DG, Kopetz S. Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. *J Natl Compr Canc Netw*. 2017;15(3):411–419
72. Leggett, B. and Whitehall, V. Role of the Serrated Pathway in Colorectal Cancer Pathogenesis. *Gastroenterology*. 2010;138(6), pp. 2088–2100. doi: 10.1053/j.gastro.2009.12.066.
73. Li, Z. N. *et al.* BRAF and KRAS mutations in metastatic colorectal cancer: Future perspectives for personalized therapy. *Gastroenterology Report*. 2020;8(3), pp. 192–205. doi: 10.1093/gastro/goaa022.
74. Løes, I. M. *et al.* Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. *International Journal of Cancer*. 2016;139(3), pp. 647–656. doi: 10.1002/ijc.30089.
75. Lordan, J. T. *et al.* A 10-year study of outcome following hepatic resection for

- colorectal liver metastases - The effect of evaluation in a multidisciplinary team setting. *European Journal of Surgical Oncology*. 2009;35(3), pp. 302–306. doi: 10.1016/j.ejso.2008.01.028.
76. Lusikoy, R. Faktor Resiko Terjadinya Kanker Kolorektal di Indonesia. Hasanuddin University. 2017.
77. Lwanga, S. K. and Lemeshow, S. *Sample Size Determination in Health Studies: A Practical Manual*. Journal of the American Statistical Association. 1991. doi: 10.2307/2290547.
78. Ma, Y. *et al.* Type 2 diabetes and risk of colorectal cancer in two large U.S. prospective cohorts. *British Journal of Cancer*. 2018;119(11), pp. 1436–1442. doi: 10.1038/s41416-018-0314-4.
79. Makmun, D. *et al.* Changing trends in gastrointestinal malignancy in Indonesia: The Jakarta experience. *Journal of Cancer Research & Therapy*. 2014;2(9), pp. 160–168. doi: 10.14312/2052-4994.2014-24.
80. Mangi FH, *et al.* Novel molecular classification of colorectal cancer and correlation with survival. *Saudi Journal of Biological Sciences*. 2022;3929-36.
81. Margonis, G. A. *et al.* Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. *Cancer*, 2016;122(17), pp. 2698–2707. doi: 10.1002/cncr.30085.
82. Margonis, G. A. *et al.* KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases. *HPB*. 2019;21(11), pp. 1527–1534. doi: 10.1016/j.hpb.2019.03.368.
83. Mármol, I. *et al.* Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. *International Journal of Molecular Sciences*. 2017;18(1). doi: 10.3390/ijms18010197.
84. Martin, J. *et al.* Colorectal liver metastases: Current management and future perspective. *World Journal of Clinical Oncology*. 2020. doi: 10.5306/wjco.v11.i10.761.
85. Morgan, E. *et al.* Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. *Gut*. 2020. 72(2).
86. Morris, V. K. *et al.* Treatment of Metastatic Colorectal Cancer: ASCO

- Guideline. *Journal of Clinical Oncology*. 2023;41(3), pp. 678–700. doi: 10.1200/JCO.22.01690.
87. Nagtegaal, I. D. *et al.* The 2019 WHO classification of tumours of the digestive system. *Histopathology*. 2020;76(2), pp. 182–188. doi: 10.1111/his.13975.
88. National Cancer Institute. Financial Burden of Cancer Care. Cancer Trends Progress Report. Updated Ap. Available at. 2022. https://progressreport.cancer.gov/after/economic_burden#field_most_recent_estimates.
89. Nguyen, T. T. *et al.* Role of bile acids in colon carcinogenesis. *World J Clin Cases*. 2018;9(9), pp. 157–164.
90. Nojadeh, J. N., Sharif, S. B. and Sakhinia, E. Microsatellite instability in colorectal cancer', *EXCLI Journal*. 2018. 17. pp. 159–168. doi: 10.17179/excli2017-948.
91. Osei-Bordom, D. C., Sivesh, K. and Niki, C. Colorectal cancer, liver metastases and biotherapies. *Biomedicines*. 2021;9(8). doi: 10.3390/biomedicines9080894.
92. Palimaka, S., Blackhouse, G. and Goeree, R. Colon capsule endoscopy for the detection of colorectal polyps: An economic analysis. *Ontario Health Technology Assessment Series*. 2015;15(15), pp. 1–43.
93. Pang, Y. *et al.* Diabetes, plasma glucose and incidence of colorectal cancer in Chinese adults: A prospective study of 0.5 million people. *Journal of Epidemiology and Community Health*. 2018;72(10), pp. 919–925. doi: 10.1136/jech-2018-210651.
94. Peeters, P. J. H. L. *et al.* The risk of colorectal cancer in patients with type 2 Diabetes: Associations with treatment stage and obesity. *Diabetes Care*. 2015;38(3), pp. 495–502. doi: 10.2337/dc14-1175.
95. Pitroda, S. P. *et al.* Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. *Nature Communications*. 2018;9(1), pp. 1–8. doi: 10.1038/s41467-018-04278-6.
96. Poore, G. D. *et al.* Microbiome analyses of blood and tissues suggest cancer diagnostic approach. *Nature*. 2020;579(7800), pp. 567–574. doi: 10.1038/s41586-020-2095-1.

97. Price, S. and Wilson, L. *Patofisiologi Konsep Klinis dan Proses-Proses Penyakit*. 6th ed. Jakarta: Penerbit Buku KEdokteran EGC. 2016.
98. Rapado-González, Ó. *et al.* Circulating microRNAs as promising biomarkers in colorectal cancer. *Cancers*. 2019;11(7), pp. 1–16. doi: 10.3390/cancers11070898.
99. Rawla, P., Sunkara, T. and Barsouk, A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. *Przegląd Gastroenterologiczny*. 2019;14(2), pp. 89–103. doi: 10.5114/pg.2018.81072.
100. Remvikos, Y. *et al.* Increased p53 protein content of colorectal tumours correlates with poor survival. *British Journal of Cancer*. 1992;66(4), pp. 758–764. doi: 10.1038/bjc.1992.352.
101. Ribero, D., Amisano, M. and Capussotti, L. From Morphology To Biology. 2013;9, pp. 45–57.
102. Sawicki, T. *et al.* A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. *Cancer*. 2021;13(9), pp. 1–23. doi: 10.3390/cancers13092025.
103. Schreuders, E. H. *et al.* Colorectal cancer screening: A global overview of existing programmes. *Gut*. 2015;64(10), pp. 1637–1649. doi: 10.1136/gutjnl-2014-309086.
104. Sehgal, R. *et al.* Lynch Syndrome: An updated review. *Genes*. 2014;5(3), pp. 497–507. doi: 10.3390/genes5030497.
105. Shi, R. *et al.* Prediction of KRAS, NRAS and BRAF status in colorectal cancer patients with liver metastasis using a deep artificial neural network based on radiomics and semantic features. *American journal of cancer research*. 2020;10(12), pp. 4513–4526. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/33415015>
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7783758>.
106. Shussman, N. and Wexner, S. D. Colorectal polyps and polyposis syndromes. *Gastroenterology Report*. 2014;2(1), pp. 1–15. doi: 10.1093/gastro/got041.
107. Siena, S. *et al.* Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. *Journal of the*

- National Cancer Institute. 2009;101(19), pp. 1308–1324. doi: 10.1093/jnci/djp280.
108. Stewart, C. L. *et al.* Cytoreduction for Colorectal Metastases: Liver, Lung, Peritoneum, Lymph Nodes, Bone, Brain. When Does it Palliate, Prolong Survival, and Potentially Cure? *Curr Probl Surg.* 2018;55(9), pp. 330–379. doi: 10.1053/j.gastro.2016.08.014.CagY.
109. Sung, H. *et al.* Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians.* 2021;71(3), pp. 209–249. doi: 10.3322/caac.21660.
110. Thélin, C. and Sikka, S. Epidemiology of Colorectal Cancer — Incidence, Lifetime Risk Factors Statistics and Temporal Trends. *Screening for Colorectal Cancer with Colonoscopy.* 2015. doi: 10.5772/61945.
111. Thompson, S. M. *et al.* Heat Stress-Induced PI3K/mTORC2-Dependent AKT signaling is a central mediator of hepatocellular carcinoma survival to thermal ablation induced heat stress. *PLOS ONE.* 2016;11(9), pp. 1–29. doi: 10.1371/journal.pone.0162634.
112. Torén, W., Ansari, D. and Andersson, R. Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: A systematic review and meta-analysis. *Cancer Cell International.* 2018;18(1), pp. 1–16. doi: 10.1186/s12935-018-0715-8.
113. Tran, K. A. *et al.* MEK inhibitors and their potential in the treatment of advanced melanoma: The advantages of combination therapy. *Drug Design, Development and Therapy.* 2015;10, pp. 43–52. doi: 10.2147/DDDT.S93545.
114. Tsilimigras, D. I. *et al.* Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. *Surgical Oncology.* 2018;27(2), pp. 280–288. doi: 10.1016/j.suronc.2018.05.012.
115. Valle, L. *et al.* Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. *J Pathol.* 2019;247(5), pp. 574–588. doi: 10.1002/path.5229.Genetic.

116. Villéger, R. *et al.* Microbial markers in colorectal cancer detection and/or prognosis. *World Journal of Gastroenterology*. 2018;24(22), pp. 2327–2347. doi: 10.3748/wjg.v24.i22.2327.
117. Vinikoor, L. C. *et al.* Cholecystectomy and the risk of recurrent colorectal adenomas. *Cancer Epidemiology Biomarkers and Prevention*. 2007;16(7), pp. 1523–1525. doi: 10.1158/1055-9965.EPI-07-0243.
118. Vu Thi, M. T. *et al.* KRAS gene mutation in patients with primary colorectal cancer. *Acta Medica*. 2019;50(1), pp. 20–25. doi: 10.32552/2019.actamedica.337.
119. Wang H, Shan X, Zhang M, et al. Homogeneous and heterogeneous risk and prognostic factors for lung metastasis in colorectal cancer patients. *J BMC Gastroenterology*. 2022. 22:193
120. Win, A. K. *et al.* Risk prediction models for colorectal cancer: A review', *Cancer Epidemiology Biomarkers and Prevention*. 2012;21(3), pp. 398–410. doi: 10.1158/1055-9965.EPI-11-0771.
121. Wong, G. Y. M. *et al.* Recurrence patterns predict survival after resection of colorectal liver metastases. *ANZ Journal of Surgery*. 2022;92(9), pp. 2149–2156. doi: 10.1111/ans.17835.
122. Wong, M. C. S. *et al.* Differences in Incidence and Mortality Trends of Colorectal Cancer Worldwide Based on Sex, Age, and Anatomic Location. *Clinical Gastroenterology and Hepatology*. 2021;19(5), pp. 955-966.e61. doi: 10.1016/j.cgh.2020.02.026.
123. World Health Organisation *World Health Statistics 2020: Monitoring Health for the SDGs, Sustainable Development Goals*. 2020. Available at: <https://all3dp.com/2/fused-deposition-modeling-fdm-3d-printing-simply-explained/>.
124. Wu Y, et al. Gender matters: sex disparities in colorectal cancer liver metastasis survival: a population-based study. *Gut*. Sep. 2021, 70 (Suppl 2) A142-A143
125. Xie MZ, Li JL, Cai ZM, Li KZ, Hu BL. Impact of primary colorectal cancer location on the KRAS status and its prognostic value. *BMC Gastroenterol*. 2019;19:46.

126. Yamashita, S. *et al.* APC and PIK3CA Mutational Cooperativity Predicts Pathologic Response and Survival in Patients Undergoing Resection for Colorectal Liver Metastases. *Annals of Surgery*. 2017.pp. 1–6. doi: 10.1097/SLA.0000000000002245.
127. Yang, J. *et al.* American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in familial adenomatous polyposis syndromes. *Gastrointestinal Endoscopy*. 2020;91(5), pp. 963-982.e2. doi: 10.1016/j.gie.2020.01.028.
128. Young, P. E. *et al.* Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: Current status and challenges. *Journal of Cancer*. 2014;5(4), pp. 262–271. doi: 10.7150/jca.7988.
129. Zhang, Y. *et al.* ‘Cholecystectomy can increase the risk of colorectal cancer: A meta-analysis of 10 cohort studies. *PLOS ONE*.2017;12(8), pp. 1–17. doi: 10.1371/journal.pone.0181852.